Review article: The diagnosis of non-alcoholic fatty liver disease - Availability and accuracy of non-invasive methods

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 4, 2013, Pages 392-400

  Festi, D ^a   Schiumerini, R ^a   Marzi, L ^a   Di Biase, A R ^a   Mandolesi, D ^a   Montrone, L ^a   Scaioli, E ^a   Bonato, G ^a   Marchesini Reggiani, G ^a   Colecchia, A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 19; SHU 508;

ACOUSTIC RADIATION FORCE IMPULSE IMAGING; ALGORITHM; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; ECHOGRAPHY; ELASTOGRAPHY; FATTY LIVER INDEX; HUMAN; LIPID ACCUMULATION PRODUCT; LIVER FIBROSIS; MAGNETIC RESONANCE ELASTOGRAPHY; NON INVASIVE MEASUREMENT; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTON NUCLEAR MAGNETIC RESONANCE; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STAGING; TRANSIENT ELASTOGRAPHY;

BIOPSY; ELASTICITY IMAGING TECHNIQUES; FATTY LIVER; HUMANS; LIVER CIRRHOSIS; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 84872686317     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12186     Document Type: Review

References (70)

1. Younossi ZM, Stepanova M, Rafiq N, et al,. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011; 53: 1874-82.
2. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ,. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
3. Scaglioni F, Ciccia S, Marino M, Bedogni G, Bellentani S,. ASH and NASH. Dig Dis 2011; 29: 202-10.
4. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S,. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52.
5. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R,. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int 2006; 26: 856-63.
6. Shi JP, Fan JG, Wu R, et al,. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. J Gastroenterol Hepatol 2008; 23: 1419-25.
7. Vernon G, Baranova A, Younossi ZM,. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-85.
8. Weston SR, Leyden W, Murphy R, et al,. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 2005; 41: 372-9.
9. Frith J, Day CP, Henderson E, Burt AD, Newton JL,. Non-alcoholic fatty liver disease in older people. Gerontology 2009; 55: 607-13.
10. Colecchia A, Vestito A, Paltrinieri E, et al,. Associate factors of nonalcoholic fatty liver disease: results from a population-based study. Gastroenterology 2007; 132: A-744.
11. Williams CD, Stengel J, Asike MI, et al,. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-31.
12. Romeo S, Kozlitina J, Xing C, et al,. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-5.
13. Adams LA, Feldstein AE,. Nonalcoholic steatohepatitis: risk factors and diagnosis. Expert Rev Gastroenterol Hepatol 2010; 4: 623-35.
14. Cadranel JF, Rufat P, Degos F,. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477-81.
15. Kleiner DE, Brunt EM, Van Natta M, et al,. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
16. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR,. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
17. Ratziu V, Bugianesi E, Dixon J, et al,. Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability. Aliment Pharmacol Ther 2007; 26: 821-30.
18. Fukusato T, Fukushima J, Shiga J, et al,. Liver Disease Working Group-Kanto. Interobserver variation in the histopathological assessment of nonalcoholic steatohepatitis. Hepatol Res 2005; 33: 122-7.
19. Poynard T, Ratziu V, Naveau S, et al,. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005; 4: 10.
20. Poynard T, Imbert-Bismut F, Munteanu M, et al,. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004; 3: 8.
21. Myers RP, Tainturier MH, Ratziu V, et al,. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003; 39: 222-30.
22. Naveau S, Raynard B, Ratziu V, et al,. The diagnostic value of biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 2005; 3: 167-74.
23. Ratziu V, Giral P, Munteanu M, et al,. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. Aliment Pharmacol Ther 2007; 25: 207-18.
24. Lassailly G, Caiazzo R, Hollebecque A, et al,. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity. Eur J Gastroenterol Hepatol 2011; 23: 499-506.
25. Bedogni G, Bellentani S, Miglioli L, et al,. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33.
26. Gastaldelli A, Kozakova M, Højlund K, et al,. RISC Investigators. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009; 49: 1537-44.
27. Balkau B, Lange C, Vol S, Fumeron F,. Group Study D.E.S.I.R Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gastroenterol 2010; 10: 56.
28. Kozakova M, Palombo C, Paterni M, et al,. The RISC Investigators. Fatty liver index, gamma-glutamyltransferase and early carotid plaques. Hepatology 2012; 55: 1406-15.
29. Kahn HS,. The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord 2005; 5: 26.
30. Kahn HS,. The lipid accumulation product is better than BMI for identifying diabetes: a population-based comparison. Diabetes Care 2006; 29: 151-3.
31. Ioachimescu AG, Brennan DM, Hoar BM, Hoogwerf BJ,. The lipid accumulation product and all-cause mortality in patients at high cardiovascular risk: a PreCIS database study. Obesity 2010; 18: 1836-44.
32. Bedogni G, Kahn HS, Bellentani S, Tiribelli C,. A simple index of lipid over accumulation is a good marker of liver steatosis. BMC Gastroenterol 2010; 10: 98.
33. Poynard T, Ratziu V, Charlotte F, et al,. LIDO Study Group; CYTOL study group. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcohol steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6: 34.
34. Palekar NA, Naus R, Larson SP, Ward J, Harrison SA,. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int 2006; 26: 151-6.
35. Shimada M, Kawahara H, Ozaki K, et al,. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. Am J Gastroenterol 2007; 102: 1931-8.
36. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ,. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50: 1072-8.
37. Sumida Y, Yoneda M, Hyogo H,. et al. Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 257-68.
38. Campos GM, Bambha K, Vittinghoff E, et al,. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology 2008; 47: 1916-23.
39. Younossi ZM, Jarrar M, Nugent C, et al,. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 2008; 18: 1430-7.
40. Shen J, Chan HL, Wong GL, et al,. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol 2012; 56: 1363-70.
41. Musso G, Gambino R, Cassader M, Pagano G,. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-49.
42. Chalasani N, Younossi Z, Lavine JE, et al,. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.
43. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F,. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009; 51: 433-45.
44. Strauss S, Gavish E, Gottlieb P, Kantsnelso L,. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol 2007; 189: W320-3.
45. Iijima H, Moriyasu F, Tsuchiya K, et al,. Decrease in accumulation of ultrasound contrast microbubbles in non-alcoholic steatohepatitis. Hepatol Res 2007; 37: 722-30.
46. Petta S, Di Marco V, Cammà C, Butera G, Cabibi D, Craxì A,. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. Aliment Pharmacol Ther 2011; 33: 1350-60.
47. ®). Clin Res Hepatol Gastroenterol 2012; 36: 13-20.
48. ™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010; 36: 1825-35.
49. Park SH, Kim PN, Kim KW, et al,. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology 2006; 239: 105-12.
50. Cowin GJ, Jonsson JR, Bauer JD, et al,. Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. J Magn Reson Imaging 2008; 28: 937-45.
51. Meisamy S, Hines CD, Hamilton G, et al,. Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology 2011; 258: 767-75.
52. Ratziu V, Massard J, Charlotte F, et al,. LIDO Study Group; CYTOL study group. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6: 6.
53. Angulo P, Hui JM, Marchesini G, et al,. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-54.
54. Guha IN, Parkes J, Roderick P, et al,. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47: 455-60.
55. Calès P, Lainé F, Boursier J, et al,. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 2009; 50: 165-73.
56. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA,. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57: 1441-7.
57. Adams LA, George J, Bugianesi E, et al,. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2011; 26: 1536-43.
58. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP,. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 1265-9.
59. Sumida Y, Yoneda M, Hyogo H, et al,. Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol 2012; 12: 2.
60. Calès P, Boursier J, Chaigneau J, et al,. Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease. Liver Int 2010; 30: 1346-54.
61. Yoneda M, Yoneda M, Mawatari H, et al,. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008; 40: 371-8.
62. Nobili V, Vizzutti F, Arena U, et al,. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008; 48: 442-8.
63. Wong VW, Vergniol J, Wong GL, et al,. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51: 454-62.
64. Lupsor M, Badea R, Stefanescu H, et al,. Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis. J Gastrointestin Liver Dis 2010; 19: 53-60.
65. Myers RP, Pomier-Layrargues G, Kirsch R, et al,. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012; 55: 199-208.
66. de Lédinghen V, Vergniol J, Foucher J, El-Hajbi F, Merrouche W, Rigalleau V,. Feasibility of liver transient elastography with FibroScan using a new probe for obese patients. Liver Int 2010; 30: 1043-8.
67. Myers RP, Pomier-Layrargues G, Kirsch R, et al,. Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe. J Hepatol 2012; 56: 564-70.
68. Friedrich-Rust M, Romen D, Vermehren J, et al,. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. Eur J Radiol 2012; 81: e325-31.
69. Colombo S, Buonocore M, Del Poggio A, et al,. Head-to-head comparison of transient elastography (TE), real-time tissue elastography (RTE), and acoustic radiation force impulse (ARFI) imaging in the diagnosis of liver fibrosis. J Gastroenterol 2012; 47: 461-9.
70. Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL,. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 2011; 259: 749-56.